Editorji is a popular short video news and information platform based in India. It was founded in 2018 by Vikram Chandra, one of India’s leading journalists, and has risen to prominence in the digital news space in a relatively short span of time. The platform is primarily designed for mobile devices, with applications available for Android and iOS.

ABOUT US:

about us editorji

Latest Video News: Editorji provides the latest news video headlines, latest videos clip from India and the World. Get all breaking news videos on Entertainment, Business, Coronavirus, Elections, Politics and more.

Latest Video News, Breaking News, Bollywood, Political, Sports, Business News | Editorji

+91 11 4035 6666 / info@editorji.com
3rd floor, Plot B, Khasara no 360, Sultanpur, New Delhi, Delhi 110030
<a title="mail to us" href="mailto:info@editorji.com">Send Feedback</a>
<a title="Contact Us" href="mailto:info@editorji.com">Contact Us</a>

REACH US

Contact for any questions, suggestions, comments, feedback or advertisement on Editorji.com, we are always looking forward to hearing from you.

Contact Us for Feedback, Suggestions and Advertising 

Editorji content is better experienced in our app.

Zydus Cadila will be in focus today as an announcement for children vaccination is expected today.
The National Technical Advisory Group on Immunisation (NTAGI), the Covid-19 advisory group in India, will meet today to discuss vaccination for children, alongside other issues like booster dose.
As of now, only Zydus Cadila's ZyCoV-D has been approved for emergency use in India for children above 12 years old.
This comes as India reported 17 more cases of Omicron variant of Covid-19 on Sunday, taking the tally to 21.

Stock in focus: Cadila Health, As kids vaccination roll-out to be announced for Zycov-D

Zydus Cadila will be in focus today as an announcement for children vaccination is expected today.

Stock to watch

The Covid-19 advisory group in India will meet today to discuss vaccination for children alongside&nbsp;other issues like booster dose.

Zydus&nbsp;Cadila&nbsp;will be in focus today as an announcement for children vaccination is expected today.The stock which hit a high of Rs 668/share in July end has been reeling under pressure since due to the lack of clarity on the kid vaccine rollout.&nbsp;
As of now, only Zydus&nbsp;Cadila's&nbsp;ZyCoV-D has been approved for&nbsp;emergency use in India&nbsp;for children above 12 years old.
The National&nbsp;Technical Advisory Group on Immunisation (NTAGI), the Covid-19 advisory group in India, will meet today to discuss vaccination for children, alongside other issues like booster dose.
This comes as India reported 17 more cases of Omicron variant of Covid-19 on Sunday, taking the tally to 21.

Drug firm Zydus Cadila on Monday said it has received an order to supply one crore doses of its Covid-19 vaccine, ZyCoV-D, to the Indian government at ₹265 per dose.&nbsp;
The vaccine will be administered using a needle-free applicator as opposed to traditional syringes. The pharma&nbsp;giant will provide the applicator at ₹93 per dose, exlcuding&nbsp;GST.&nbsp;
The company has said that the pricing has been decided in consultation with the Government of India
ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed&nbsp;indigenously by the company against the Covid-19 virus, Zydus Cadila said.
ZyCoV-D&nbsp;is also the first vaccine cleared by India's drug regulator for inoculation of those aged 12 years and above.
The three doses of ZyCoV-D, are to be administered 28 days apart. The vaccine was given emergency use authorization by the Indian drug regulator on August 20, this year.

Zydus Cadila to supply 1 crore Covid-19 vaccine doses to India at ₹265/dose

Zydus Cadila to supply 1 crore Covid-19 vaccine doses to India at ₹265/dose along with a needle-free applicator at ₹93/dose

Zydus&nbsp;Cadila&nbsp;to sell its Covid&nbsp;vaccine to Indian govt for&nbsp;₹265/dose ZyCoV-D is a three-dose Covid-19 vaccine The doses are to be administered 28 days apart
The vaccine will given via a needle-free applicator
ZyCoV-D: first DNA plasmid vaccine for human use
ZyCoV-D: first Covid&nbsp;jab approved by India for those aged 12 and above

The vaccine will be administered using a needle-free applicator as opposed to traditional syringes.

Drug firm Zydus Cadila on Monday said it has received an order to supply one crore doses of its Covid-19 vaccine, ZyCoV-D, to the Indian government at ₹265 per dose.&nbsp;
The vaccine will be administered using a needle-free applicator as opposed to traditional syringes. The pharma&nbsp;giant will provide the applicator at ₹93 per dose, excluding&nbsp;GST.&nbsp;
Also watch:&nbsp;<a href="https://www.editorji.com/business-news/meet-zycov-d-the-world-s-first-dna-covid-19-vaccine-everything-you-need-to-know-about-the-new-vaccine-1629658709134">Meet ZyCoV-D:&nbsp;The world&rsquo;s first DNA&nbsp;Covid-19&nbsp;vaccine</a>
The company has said that the pricing has been decided in consultation with the Government of India
ZyCoV-D is the first DNA plasmid vaccine in the world for human use, developed&nbsp;indigenously by the company against the Covid-19 virus, Zydus Cadila said.
ZyCoV-D&nbsp;is also the first vaccine cleared by India's drug regulator for inoculation of those aged 12 years and above.
The three doses of ZyCoV-D, are to be administered 28 days apart. The vaccine was given emergency use authorization by the Indian drug regulator on August 20, this year.

In a bid to hasten up the vaccination drive in the country, India regulators have given the nod for a second homegrown vaccine ZyCoV-D, manufactured by Gujarat based Zyd

Meet Zycov D: The world’s first DNA Covid-19 vaccine ; everything you need to know about the new vaccine

Meet Zycov&nbsp;D: Is it really safe for kids? What is a DNA&nbsp;vaccine, How is it administered if it's needle free? All your questions answered here.&nbsp;

Meet ZyCoV-D: The world’s first DNA Covid-19 vaccine; everything you need to know about the new vaccine

The shot is &ldquo;the world&rsquo;s first and India&rsquo;s indigenously developed DNA-based vaccine for Covid-19 to be administered in humans including children and adults 12 years and above.&rdquo;

&nbsp;Zydus&nbsp;Cadila's&nbsp;covid&nbsp;vaccine&nbsp;ZyCoV-D is set to be launched in India in October and is deemed for safe for kids above 12. This&nbsp;&nbsp;'third-generation triple dose vaccine' could just be the answer to fill the gap of 100 crore&nbsp;doses required by year-end to vaccinate the vast majority of the adult population. Here is everything you need to know about this non-injecting, DNA&nbsp;vaccine which even children above 12 can take.&nbsp; Meet&nbsp;Cadila&rsquo;s ZyCoV-D
<ul>
<li>It is the world&rsquo;s first DNA vaccine to protect against Covid&nbsp;19. Requires a triple dose for immunity and showcased 67% efficacy in trials. The vaccine is deemed safe for children above the age of 12.&nbsp;</li>
</ul>
What kind of vaccine is it? How is it different than Covishield&nbsp;and Covaxin?
<ul>
<li>Cadila&rsquo;s ZyCoV-D is a plasmid DNA vaccine that introduces a DNA sequence encoding the antigen in the body and not a weakened form of the pathogen like Covaxin.&nbsp;</li>
</ul>
How does a DNA&nbsp;vaccine work?
<ul>
<li>Often referred to as the third-generation vaccines, the dose carries the genetic code of the virus that triggers the build up of immunity in one's body.&nbsp;</li>
<li>Zydus&nbsp;stated that&nbsp;the plasmid DNA platform is &ldquo;ideally suited for dealing with <a href="https://www.editorji.com/covid-19" target="_blank">Covid-19</a> as it can be easily adapted to deal with mutations in the virus, such as those already occurring&rdquo;.</li>
</ul>
Is a&nbsp;DNA&nbsp;vaccine being used anywhere else in the world?
<ul>
<li>No DNA vaccine has been widely used against any disease so&nbsp; far, but they are more stable and easier to store than mRNA shots (tech used by Pfizer &amp; Moderna)</li>
<li>According to the U.S. National Library of Medicine, over 160 different DNA vaccines are currently being tested in human clinical trials in the United States. It is estimated that 62% of these trials are devoted to cancer vaccines and 33% are applied for vaccines against human immunodeficiency virus (HIV).</li>
</ul>
How many doses does one need?
<ul>
<li>Unlike most other Covid-19 vaccines, which require two doses for full immunity, ZyCoV-D is administered in three doses. The vaccine is also needle-free.</li>
<li>The doses will be administered 28 days apart</li>
</ul>
Needle-free vaccine, how does one get the dose?
<ul>
<li>Doses are given using a device that delivers fluid through a spring-powered jet that penetrates the skin, developed by Pharmajet&rsquo;s Tropis.</li>
<li>Zydus Cadila claims this method of delivery is painless and could also reduce side effects from the jab</li>
</ul>
Is it safe? What are the trial results showing?
<ul>
<li>The vaccine has been tested on almost 30,000 participants across Phase I, II and III studies, and is the first vaccine in India to be tested on 12 to 18-year-olds. Around 1,000 participants were enrolled in the adolescent age group, among whom the vaccine was found to be safe and well-tolerated, with similar findings in the adult population</li>
</ul>
&nbsp;

India is set to have its fifth Covid-19 vaccine soon. Reports suggest that an expert committee of the Indian drug regulator has recommended approving of ZyCoV-D, Zydus Cadila's three-dose Covid-19 vaccine, for emergency use authorization or EUA.
Cadila Healthcare Ltd., an Ahmedabad-based Pharmaceutical firm, had applied for EUA on July 1 for its three-dose Covid-19 vaccine. The expert committee has asked the drugmaker to submit additional data for the 20dose regimen of its vaccine.
India's largest clinical trial of Covid-19 vaccine was conducted by Zydus Cadila which showed 66.66% against symptomatic Covid cases and 100% for moderate cases. ZyCoV-D vaccine was also tesed in about 1000 subjects between the age group of 12-18 group for the first time and was found to be safe and very well tolerated.
ZyCoV-D is a plasmid DNA vaccine which is applied using a 'needle free injector' which Zydus claims it significatly reduces side-effects.

Zydus Cadila's 3-dose vaccine gets approval, 1st jab for children above 12 in India

India is set to get its fifth Covid-19 vaccine as reports suggest that&nbsp;Zydus Cadila's 3-dose vaccine has got approval. The vaccine will be the 1st jab for children above 12 in India

Zydus Cadila's 'needle-free' Covid-19 vaccine gets approval 

//Vaccine for children:&nbsp;Zydus Cadila's&nbsp;ZyCoV-D gets govt approval //Three-dose Covid-19 vaccine gets nod for emergency use&nbsp; //Children between 12-18 age bracket can get&nbsp;ZyCoV-D jab //Cadila&nbsp;to submit&nbsp;additional data to authorities for the 20 dose regimen&nbsp; //Tested on 1,000 subjects, the vaccine fared&nbsp;66.66%&nbsp;against symptomatic cases //The plasmid DNA vaccine is applied using a needle free injector

Zydus Cadila's three-dose Covid-19 vaccine gets approval for emergency use authorization.&nbsp;ZyCoV-D vaccine became India's 5th Covid-19 vaccine which&nbsp;went through India's largest clinical trial testing on&nbsp;adolescent population.

India is set to have its fifth Covid-19 vaccine soon. Reports suggest that an expert committee of the Indian drug regulator has recommended approving of ZyCoV-D, Zydus Cadila's three-dose Covid-19 vaccine, for emergency use authorization.
ZyCoV-D is a 12-year-old onward vaccine and there were 28,000 trial pool which included under 18 candidates as well.&nbsp; Cadila Healthcare Ltd., an Ahmedabad-based Pharmaceutical firm, had applied for authorisation on July 1 for its three-dose Covid-19 vaccine. The expert committee has asked the drugmaker to submit additional data for the 20 dose regimen of its vaccine.
 India's largest clinical trial of Covid-19 vaccine was conducted by Zydus Cadila which showed 66.66% against symptomatic Covid cases and 100% for moderate cases. ZyCoV-D vaccine was also tested in about 1000 subjects between the age group of 12-18 group for the first time and was found to be safe and very well tolerated.
 ZyCoV-D is a plasmid DNA vaccine which is applied using a 'needle free injector' which Zydus claims it significatly reduces side-effects.

Gujarat-based pharma giant Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Fulvestrant injection, used in the treatment of breast cancer.
Zydus Cadila said this injection is either used alone or in combination with other drugs to treat certain types of advanced breast cancer cases.Zydus will now market the jab as 250 mg/5 mL or 50 mg/mL as a single-dose in pre-filled syringes.
The injection will be used in breast cancer cases where tumours are dependant on hormones such as estrogen to grow, or in cases where the breast cancer has spread to other parts of the body in women who are post-menopausal.
Also watch:&nbsp;Is it safe for breastfeeding mothers to take medicines like paracetamol and aspirin?
This injection will be manufactured at Zydus Cadila's formulation manufacturing facility at Zydus Biologics, Ahmedabad.

Zydus Cadila gets US FDA nod for Fulvestrant jab for breast cancer treatment

Zydus Cadila gets US FDA nod to market&nbsp;Fulvestrant injection for breast cancer treatment

//Zydus&nbsp;Cadila receives&nbsp;US FDA approval&nbsp;for breast&nbsp;cancer injection //Gujarat-based pharma&nbsp;company&nbsp;to market Fulvestrant injection //Injection is used alone or with other drugs to treat some cases //Zydus will market jab as 250 mg/5 mL or 50 mg/mL in a single-dose //Pharma&nbsp;giant&nbsp;to manufacture&nbsp;the pre-filled syringes in Ahmedabad

Zydus Cadila has received final approval from US Food and Drug Administration to market Fulvestrant Injection. This injection is used in the treatment of breast cancer.

Gujarat-based pharma giant Zydus Cadila has received final approval from the US Food and Drug Administration (USFDA) to market Fulvestrant injection, used in the treatment of breast cancer.
Zydus Cadila said this injection is either used alone or in combination with other drugs to treat certain types of advanced breast cancer cases. Zydus will now market the jab as 250 mg/5 mL or 50 mg/mL as a single-dose in pre-filled syringes.
The injection will be used in breast cancer cases where tumours are dependant on hormones such as estrogen to grow, or in cases where the breast cancer has spread to other parts of the body in women who are post-menopausal.
Also watch:&nbsp;<a href="https://www.editorji.com/story/is-it-safe-for-breastfeeding-mothers-to-take-medicines-like-paracetamol-and-aspirin-1626436894257" target="_blank">Is it safe for breastfeeding mothers to take medicines like paracetamol and aspirin?</a>
This injection will be manufactured at Zydus Cadila's formulation manufacturing facility at Zydus Biologics, Ahmedabad.

Union Health Minister Mansukh Mandaviya on Tuesday told Rajya Sabha that India will be the first country to develop a DNA-based Covid-19 vaccine even as other manufactures are steadily ramping up production.
&ldquo;It is a matter of great pride for us that our scientists will be the first to develop a DNA vaccine,&rdquo; the minister said.
Mandaviya was referring to drug maker Zydus Cadila, which has applied for emergency use authorisation of its DNA vaccine.
Also watch:&nbsp;67.6% Indians have Covid-19 anti-bodies, 40 crore still vulnerable: Health Ministry
Mandaviya said while Serum Institute of India has begun providing 11-12 crore doses of Covishied vaccine every month, Biological E is conducting third-phase trial of its vaccine, which is expected to come in the market by September-October with 7.5 crore doses. 

Health Minister Mansukh Mandaviya: India will be first to make DNA-based jab

Health Minister Mansukh Mandaviya&nbsp;informed the Rajya&nbsp;Sabha&nbsp;that&nbsp;India will be first nation to develop a&nbsp;DNA-based jab for Covid

BITE IN RAJYA SABHA YESTERDAY &ldquo;It is a matter of great pride for us that our scientists will be the first to develop a DNA vaccine,&rdquo;
SUPERS
// India will be the first nation to develop DNA vaccine for Covid // Health Minister says it is a matter of great pride for the nation // Zydus Cadila applied for emergency use authorisation of its DNA vaccine // Serum Institute supplying 11-12 crore doses of Covishied every month // Biological E is currently conducting third-phase trial of its vaccine

Mandaviya was referring to drug maker Zydus Cadila, which has applied for emergency use authorisation of its DNA vaccine.

Union Health Minister Mansukh Mandaviya on Tuesday told Rajya Sabha that India will be the first country to develop a DNA-based Covid-19 vaccine even as other manufactures are steadily ramping up production.
&ldquo;It is a matter of great pride for us that our scientists will be the first to develop a DNA vaccine,&rdquo; the minister said.
Mandaviya was referring to drug maker Zydus Cadila, which has applied for emergency use authorisation of its DNA vaccine.
Also watch:&nbsp;<a href="https://www.editorji.com/story/67-6-indians-have-covid-19-anti-bodies-40-crore-still-vulnerable-health-ministry-1626791635824" target="_blank">67.6% Indians have Covid-19 anti-bodies, 40 crore still vulnerable: Health Ministry</a>
Mandaviya said while Serum Institute of India has begun providing 11-12 crore doses of Covishied vaccine every month, Biological E is conducting third-phase trial of its vaccine, which is expected to come in the market by September-October with 7.5 crore doses.

zydus cadila

Categories